论文部分内容阅读
８名健康志愿者口服依诺沙星原粉及片剂后的体内过程符合血管外一室模型。单剂空腹口服原粉和片剂４００ｍｇ的平均血高峰浓度分别为３．６５±１．１３ｍｇ／Ｌ和３．１４±０．９２ｍｇ／Ｌ，消除半衰期分别为４．７４±０．７５ｈ和４．８２±０．７２ｈ，经统计学处理，原粉及片剂的Ｃｍａｘ，Ｔ１／２ｋｅ，ＡＵＣ均无显著性差异。与原粉比较，片剂的相对生物利用度为１０１．４％。单剂空腹口服原粉、片剂４００ｍｇ后２４ｈ的尿排出率为５２．８％和５４．５％，有效尿浓度可维持至１２～２４ｈ之久。根据依诺沙星的药动学研究结果，制订对各种感染的给药方案。
The in vivo process of oral administration of enoxacin powder and tablets in eight healthy volunteers conformed to the extravascular external compartment model. The mean peak blood concentrations of 400mg single-dose fasting oral powder and tablet were 3.65 ± 1.13mg / L and 3.14 ± 0.92mg / L respectively, with the elimination half-lives of 4.74 ± 0.75h and 4 .82 ± 0.72h, after statistical analysis, the original powder and tablet Cmax, T1 / 2ke, AUC no significant difference. Compared with the original powder, the relative bioavailability of tablets was 101.4%. Single oral fasting oral powder, 400mg tablets 24h urinary excretion rate of 52.8% and 54.5%, effective urine concentration can be maintained to 12 ~ 24h long. According to enoxacin pharmacokinetic research results, develop a variety of infections dosing program.